Draft versioned claims from your manuscript with linked experiments, exact results, limitations, falsifiability notes, and provenance for reviewers.Know what the science actually supports before you trust the answer.
Press Enter β΅ to import
Explore by Goal
"I was taught that the way of progress was neither swift nor easy."
- Marie Curie
Quick Explanation
Copied
Yong Yi β scientific strength (evidence-based, skeptical take)
From the provided paper set, there is strong experimental/mechanistic rigor in several biomedical studies (e.g., conditional genetics, multi-modal validation, omics integration) including TgPPKL in Toxoplasma () and spatial omics for OSCC ().
However, the author pool identification is ambiguous (multiple βYong Yiβ matches exist in OpenAlex), so attribution to a single biomedical researcher cannot be confirmed from the provided metadata alone.
Across the biomedical excerpts you provided, a recurring weakness is translation fragility: many studies show impressive mechanism + preclinical evidence, but have limitations like cross-sectional sampling, model dependence, limited cohorts, or reliance on computational interaction inference.
Long Explanation
Author Review: Yong Yi (critical, evidence-based)
Scope note: Your input contains (i) an author citation-metric snapshot and (ii) a large set of paper excerpts with DOIs and extracted evidence. This review evaluates the scientific strength of the provided paper excerpts and the provided citation-metric snapshot; it does not infer additional authorship beyond what your data supports.
What this plot does / does not do
Scores are taken verbatim from your provided excerpt metadata (e.g., βpaper_scientific_quality_scoreβ). This figure does not replace reading each paperβs methods/results.
Evidence highlights from the provided excerpt DOIs
Only claims below are tied to the provided excerpt content and cited DOIs.
TurboID proximity labels can be indirect; potential incomplete degradation/off-target auxin effects; modest in vivo group sizes and single mouse strain limit generalization.
Human cohort epidemiology (macrosomia)
Large multicenter dataset (tens of thousands); uses inverse probability weighting and GLMM with hospital random effects; quantifies population-attributable fractions.
Cross-sectional design limits causal inference; missingness and possible undiagnosed diabetes; no gestational weight gain data; residual confounding/hospital/region differences remain possible.
OSCC spatial immunology (ANXA1βFPR)
Uses scRNA-seq + spatial transcriptomics + multiplex IHC; explicitly maps spatial MDSC distributions and tests an FPR2 blockade + anti-PD-1 combination in mouse models.
Cross-sectional sampling (early vs late) constrains causal temporal claims; deconvolution/ligandβreceptor inference depends on computational assumptions; translation to broader human OSCC heterogeneity needs more validation.
On-target toxicity (CRBN molecular glues)
Humanized knock-in mouse models; CRBN-dependent toxicity; rescue by non-degradable target allele; transcriptome + proteome collapse analysis and proximity labeling to distinguish direct vs downstream effects.
Translational boundaries to humans remain uncertain; rescue allele is not a deployable therapy; generality across degraders/species needs further safety cataloging.
Species discovery (Polygonatum plastome phylogenomics)
Integrative taxonomy: cpDNA phylogenomics (multi-sample variation) + morphology + formal type deposition and GenBank accessions.
cpDNA alone can mislead if nuclear introgression/lineage sorting occurs; geographic sampling may still underrepresent intraspecific variation.
Interpretation (with skepticism)
Many excerpt scores are high on novelty and usefulness, which suggests the research direction often targets mechanistic or translationally relevant gaps.
But because these are provided scoring metadata, they are not independently verified here; real scientific value must be judged by the methods, effect sizes, controls, and reproducibility details in the full text.
Scientific strength: patterns across the excerpt set
Several provided biomedical excerpts use a hallmark βcausality ladderβ: perturb (genetic/chemical/system-level), measure multiple downstream phenotypes, and verify specificity via rescue or dependency logic.
TgPPKL: conditional degradation + complementation links genotype β morphology/replication/virulence phenotypes, with proximity proteomics used for mechanistic context rather than overclaiming direct binding.
The OSCC excerpt combines scRNA-seq + spatial transcriptomics + multiplex IHC, then validates therapeutic relevance in mouse models. This is scientifically favorable because independent modalities constrain the hypothesis.
The GSPT1 molecular glue toxicity excerpt is notable for treating βtoxicityβ as mechanistic dataβusing a non-degradable allele to test on-target causality and to delineate what could (and could not) be downstream.
4) Where the excerpt set is weaker: translation limits + inference dependence
Common blind spots (not unique to this author) include:
Model dependence: mouse or in vitro systems may not preserve human complexity (immune repertoire, tissue architecture, temporal progression).
Computational interaction inference: ligandβreceptor or pathway enrichment can be hypothesis-generating; without direct biochemistry/proximity validation, mechanistic claims should be tightly scoped.
Study design ceilings: cross-sectional comparisons constrain causal temporal inference even when the story is compelling.
Example: the OSCC excerpt flags that deconvolution/interaction inference and limited patient/sample counts affect confidence about generality.
Attribution & citation-metric skepticism
Your message includes a citation-metric snapshot (h-index=1, citations=3, paper count=5) plus a list of papers. These metrics do not establish biomedical expertise; they only indicate limited citation footprint in that specific index snapshot you provided.
Separately, you provided OpenAlex βmatchesβ for the query βYong Yiβ that include multiple different people with similar names. That means name disambiguation is an open problem; it is scientifically unsafe to treat all βYong Yiβ DOIs as belonging to one person.
Because the OpenAlex matches were supplied as metadata without DOI citations, I cannot validate who authored the specific biomedical excerpt DOIs solely from those lists here.
The most defensible conclusion is:
the provided excerpt papers show a range of methods and (in several cases) strong causal and multi-modal evidence, but identity attribution across all excerpts remains uncertain without a verified author identifier (e.g., ORCID) linked to each paper.
Summarize the provided DOI set into a score table, compute correlations (quality vs reproducibility; novelty vs usefulness), and render a labeled Plotly dashboard for rapid cross-paper comparison.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A common alternative would claim that spatial omics βcell-cell communicationβ scores by themselves are sufficient to identify the therapeutic axis; this is less compelling because proximity/inference can be indirect and thresholded, and falsification requires perturbation-linked spatial redistribution.
Another strongman hypothesis: any target degradation causing lethality automatically implies direct toxicity from that target alone; rescued by non-degradable allele logic in the provided toxicity excerpt, which indicates much of the damage can be downstream system failure.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Analysis 
Hypothesis Graveyard
Discussion